Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition

July 26, 2013 updated by: Glenda Courtney-Martin, The Hospital for Sick Children

Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition: Is There a Problem in Canada?

The purpose of this study is to determine whether children on long-term parenteral nutrition (>6 weeks) have serum aluminum concentrations that are higher than children (aged and gender matched) that have never received parenteral nutrition.

Study Overview

Detailed Description

Aluminum contamination of parenteral nutrition (PN) solutions has been a concern for decades because of its link to metabolic bone disease (MBD) due to it's high aluminum content. Currently in the United States, FDA regulations are in place to protect American patients on PN from the effects of aluminum (AL) toxicity. Despite these regulations, pediatric patients on PN are still receiving higher than recommended AL intakes from PN.

Unlike the United States, there are no regulations governing AL content of or intakes from PN solutions in Canada. Consequently, the investigators are unaware of the AL content of the various PN solutions given to our patients. The investigators (the authors) have observed that a significant number of our patients on long-term PN (Home PN), have MBD. Some of our patients have also had bone fractures. The investigators have also observed alteration in calcium and phosphate concentrations as well as suppressed PTH. In an effort to understand the etiology of the MBD the investigators have measured serum AL concentrations in our patients and have found them to be high; between 900 - 2000 nmol/L compared to 0 to 220 nmol/L reported in healthy adults. This has led us to believe that there is a significant problem of AL contamination in PN solutions in Canada. Because the investigators are unable to obtain information on the AL content of the various PN solutions from the PN suppliers, the investigators have decided to report on the serum AL concentrations of our patients as well as the AL concentration of a random sample of PN solutions provided to patients. Plasma aluminum concentrations have already been analyzed in each of the cases. Blood was drawn for routine clinical monitoring on each subject after they had been on PN for six weeks or more.

This is the first step towards raising awareness of the potential problem. It is our hope that this will provide initial evidence to help guide Health Canada's decision regarding regulations on AL content in PN solutions in Canada.

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 month to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients followed in the Home-TPN program at the Hospital for Sick Children

Description

Inclusion Criteria:

For Cases on Long-term PN:

  1. On PN for ≥ 6 consecutive weeks
  2. Has had serum AL concentration drawn and recorded in the past

For Control Subjects:

  1. Currently patients at the Hospital for Sick Children being followed on an inpatient ward or in an ambulatory clinic
  2. Are not on PN and have never received PN in the past
  3. Fed by mouth or enterally with feeding tube

Exclusion Criteria:

For Cases on Long-term PN

  1. Patients who are on PN for shorter than 6 weeks
  2. Patients who never had serum AL concentration measured
  3. Patients who received albumin infusion before blood draw for Al concentration
  4. Patients on hemodialysis

For Control Subjects

  1. Patients who are not able to be matched to a case/subject on long-term PN for age and gender
  2. Patients who do not require blood work as a part of routine clinical monitoring
  3. Patients who are on PN
  4. Patients with known renal impairment
  5. Patients who received albumin infusion before blood draw for Al concentration -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
On long-term PN
Never been on TPN

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum aluminum concentration
Time Frame: 5 months
A 4 ml blood sample will be obtained from each control subject when they are giving blood for routine clinbical purposes. These subjects will be recruited from in-patient wards or ambulatory clinics. The aluminum content of samples (plasma aluminum concentration) will be determined by high resolution sector field inductively coupled mass spectrometry (HR-SF-ICP-MS). The accuracy and precision of the instrument used to determine aluminum concentration is measured using external and internal standards. Accuracy and precision was last measured at ± 0.5 to 2.5% and 5 to 10% respectively
5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Glenda Courtney-Martin, MSc, PhD, RD, The Hospital for Sick Children

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

June 8, 2011

First Submitted That Met QC Criteria

June 9, 2011

First Posted (Estimate)

June 10, 2011

Study Record Updates

Last Update Posted (Estimate)

July 29, 2013

Last Update Submitted That Met QC Criteria

July 26, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 1000025865

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aluminum Contamination of Parenteral Nutrition

3
Subscribe